



INDIVIOR

Forward-looking statements

This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance for 2021 and its medium- and long-term growth outlook, its operational goals, its product development pipeline and statements regarding ongoing litigation and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions.

Various factors may cause differences between Indivior's expectations and actual results, including, among others (including those described in the risk factors described in the most recent Indivior PLC Annual Report and in subsequent releases): factors affecting sales of Indivior Group's products and financial position; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group's drug applications or authorizations; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved, if at all; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing and in the supply chain; disruptions in or failure of information technology systems; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; challenges in the commercial execution; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group's products and product candidates; risks related to legal proceedings, including compliance with the Indivior Group's agreements with the U.S. Department of Justice and with the Office of Inspector General of the Department of Health and Human Services, non-compliance with which could result in potential exclusion from participating in U.S. Federal health care programs; the ongoing investigative and antitrust litigation matters; the opioid national multi-district litigation and securities class action litigation; the Indivior Group's ability to protect its patents and other intellectual property; the outcome of patent infringement litigation relating to Indivior Group's products, including the ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; risks related to the evolving COVID-19 pandemic and the potential impact of COVID-19 on the Indivior Group's operations and financial condition, which cannot be predicted with confidence; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.



Today's key takeaways

- Continued good execution across all Strategic Priorities
- Organized Health System (OHS) focus for SUBLOCADE® delivering
- Moving forward with confidence – executing \$100m share repurchase program



Strategic Priorities report card: Q2 2021

1

Grow SUBLOCADE® >\$1 bil.

- **Q2 21 NR:** \$61m
+42% vs. Q1 21;
+110% vs. Q2 20
- **Q2 21 US dispenses:** 43.0k*
+20% vs. Q1 21;
+60% vs. Q2 20
- **Q2 21 SUBLOCADE patients**:** 36.9k
+15% vs. Q1 21;
+60% vs. Q2 20
- **Q2 21 OHS activation:**
>49%* of NR now from OHS channel;
approx. 250 OHS activated (targeting 500+)

ONCE-MONTHLY
Sublocade[®]
(buprenorphine extended-release)
injection for subcutaneous use
100mg/300mg

2

Diversify Revenue

- **SUBUTEX® Prolonged Release (ROW):**
Q2 21 NR: \$4m
+33% vs. Q1 21
available in Australia, Canada and Israel; recently approved in Germany and Italy
- **PERSERIS Q2 21 NR:** \$4m
+33% vs. Q1 21 and Q1 20
- **SUBOXONE® Film (ROW):** now available in Canada, Germany, the Nordics and the UK



3

Build Our Pipeline

- **SUBLOCADE® Post Marketing Commitments:** All approved by FDA and considered closed
- **SUBLOCADE® label:** updated to include relevant fentanyl pharmacodynamic study (FDA approved)
- **Aelis Farma (AEF 0117):** entered exclusive option for leading mid-stage asset targeting cannabis-related disorders
- **INDV-2000 & INDV-1000:** Respective development studies and plans on-track



4

Optimize Operating Model

- **Cash:** \$1bn
+\$142m vs. FYE 2020
- **Net Cash:** \$750m
+\$127m vs. FYE 2020
- **Completed Term Loan Refinancing**
- **Sold TEMGESIC® / BUPREX® / BUPREXX® (buprenorphine) analgesic business for ~\$21m of cash*****



* Excludes units related to CJS order

** Rolling 12-month patients estimate using both Specialty Pharmacy and Specialty Distributor proxy data

*** Closed in early July 2021; cash proceeds not included in H1 / Q2 2021 financials

FY 2021 guidance reiterated

FY 21 Guidance (\$ in mil.)	
Total NR <ul style="list-style-type: none">• SUBLOCADE NR• PERSERIS NR	\$705m to \$740m <ul style="list-style-type: none">• \$210m to \$230m• \$17m to \$20m
Adj. gross margin	Low 80% range
Adj. OPEX (SG&A + R&D)	\$470m to \$480m
Adj. pre-tax income	Positive

Additional top-line items:

- Continued strong underlying BMAT market growth
- F/X translation benefits of ~\$10m
- SUBOXONE® Film
 - ✓ More modest share erosion in FY21
 - ✓ The Group continues to expect that SUBOXONE® Film share loss will ultimately revert to observed industry analogues⁽¹⁾
- Rest of World
 - ✓ Availability of new products (SUBUTEX PR, SUBOXONE Film) offset by continued austerity measures in legacy Western European markets resulting in relatively unchanged NR versus FY 2020

Margin & Expense detail:

- Mid single digit decline in FY 2021 adj. gross margin primarily due to current product and regional mix; adj. GM expected to return to mid-80's in 2022 as more profitable SUBLOCADE is expected to grow as a proportion of total NR.
- Adj. OPEX (combined SG&A and R&D) of \$470m to \$480m reflects:
 - ✓ Benefits from completed strategic alignment in 2020;
 - ✓ More than offset by incremental investments for US LAI technologies of up to \$25m fueled by the relative share resilience of SUBOXONE Film in the US; and,
 - ✓ COVID-delayed LAI capacity expansion projects.

